Appendiceal Neuroendocrine Neoplasms: an Update for 2023

Curr Oncol Rep. 2024 Feb;26(2):114-120. doi: 10.1007/s11912-023-01484-4. Epub 2024 Jan 2.

Abstract

Purpose of review: To summarize the literature from the last 5 years on treatment of appendiceal neuroendocrine neoplasms (aNEN). Furthermore, to evaluate the prognostic significance of lymph node metastases, indications for adjuvant treatment, and challenges of the current follow-up regimen.

Recent findings: Simple appendectomy is sufficient in tumors < 1 cm while extended surgery is indicated in tumors > 2 cm. In a multicenter study of aNENs measuring 1-2 cm, extended surgery offered no significant prognostic advantage and is now limited to incomplete tumor resection or high-grade G2 or G3 aNEN. Follow-up remains debatable, as the use of imaging and biomarkers lacks validation. While surgical procedure is well established in aNEN tumors < 1 cm and > 2 cm, the need for extended surgery in aNEN tumors 1-2 cm is questionable. Future studies should address the prognostic impact of lymph node metastases and the optimal design and duration of follow-up.

Keywords: Appendiceal; Follow-up; Neuroendocrine neoplasm; Treatment.

Publication types

  • Review

MeSH terms

  • Appendectomy
  • Appendiceal Neoplasms* / pathology
  • Appendiceal Neoplasms* / surgery
  • Humans
  • Lymphatic Metastasis
  • Multicenter Studies as Topic
  • Neuroendocrine Tumors* / diagnosis
  • Neuroendocrine Tumors* / surgery
  • Prognosis
  • Retrospective Studies